Skip to main content
. 2018 May 8;2:13. doi: 10.1038/s41698-018-0056-z

Fig. 5.

Fig. 5

Comorbidities contributing to the vascular nature of VSP inhibitor cardiotoxicity. Illustration of the comorbidities to consider and to screen for in patients who are considered for VSP therapy matching the pathophysiological concept introduced in Fig. 4